SCHEMBL15026752

SCHEMBL15026752

CCCCc1nc(-c2ccc(F)c(C)c2)n[nH]1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DDX3X O00571 1/20 0.43
SUCNR1 Q9BXA5 1/20 0.43
ADORA2A P29274 3/20 0.43
ADORA1 P30542 2/20 0.40
AOC3 Q16853 2/20 0.40
TGFBR1 P36897 1/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
POLB P06746 1/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39
GRIN2B Q13224 1/20 0.39
NR1H2 P55055 2/20 0.38
QPCT Q16769 1/20 0.37
ROCK2 O75116 2/20 0.36
NR1H3 Q13133 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15025171 0.96 SUCNR1 (0.43) DDX3XSUCNR1ADORA2AADORA1AOC3
SCHEMBL15025491 0.92 AOC3 (0.46) SUCNR1ADORA2AADORA1AOC3TGFBR1
SCHEMBL15025603 0.86 TGFBR1 (0.47) SUCNR1ADORA2AADORA1TGFBR1RAB9A
SCHEMBL15026753 0.83 ADORA2A (0.42) SUCNR1ADORA2AADORA1AOC3TGFBR1
SCHEMBL7658956 0.81 DDX3X (0.50) DDX3XSUCNR1ADORA2AADORA1AOC3
SCHEMBL26108539 0.80 ADORA2A (0.47) DDX3XADORA2AADORA1RAB9ANPC1
SCHEMBL15026720 0.80 ADORA2A (0.44) ADORA2AADORA1TGFBR1RAB9ANPC1
SCHEMBL15026739 0.76 HDAC3 (0.46) ADORA2AAOC3TGFBR1
SCHEMBL5381307 0.75 CSNK1D (0.63) DDX3XSUCNR1ADORA1MAPK1
SCHEMBL15026718 0.75 NR1H2 (0.49) ADORA2AADORA1RAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2804854-B1 SUBSTITUTED TRIAZOLES AND THEIR USE FOR TREATMENT AND/OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS BOEHRINGER INGELHEIM INT (DE) 2016-03-16 EP disclosed
US-8889677-B2 Substituted triazoles useful as mGlu5 receptor modulators Boehringer Ingellheim International GmbH (DE) 2014-11-18 US disclosed
US-8642774-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-04 US disclosed
WO-2013107761-A1 SUBSTITUTED TRIAZOLES AND THEIR USE FOR TREATMENT AND/OR PREVENTION NEUROLOGICAL AND PSYCHIATRIC DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-07-25 WO disclosed
US-20130184248-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-07-18 US disclosed
US-20130150341-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150341-A1 NOVEL COMPOUNDS GRM5, GRM1, GRIK5 DDX3X 2133/4885SUCNR1 448/4885ADORA2A 79/4885
US-20130184248-A1 NOVEL COMPOUNDS GRM5, GRIN1, GRM1 DDX3X 3397/4885SUCNR1 488/4885ADORA2A 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.